Exploring ITGAD: A Potential Drug Target and Biomarker (G3681)

Target Name: ITGAD

NCBI ID: G3681

ITGAD

Exploring ITGAD: A Potential Drug Target and Biomarker

ITGAD (leukointegrin alpha D) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the integrin alpha chain, which is a family of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. ITGAD is unique among its family members because of its unique structure and function.

The search for new drug targets and biomarkers is a continuous process in the field of medicine. ITGAD, due to its unique structure and function, has been identified as a potential drug target. This article will explore ITGAD as a drug target and its potential as a biomarker.

Drug Target Potential

ITGAD is a protein that can interact with various molecules, including cytokines, growth factors, and chemotherapy drugs. Its unique structure and function make it an attractive target for drug development.

One of the key reasons for ITGAD's potential as a drug target is its role in cell-cell and cell-extracellular matrix interactions. Integrins are critical for cell-cell adhesion, and ITGAD is a member of the integrin alpha chain, which is involved in these interactions. This makes ITGAD a target for drugs that want to modulate cell-cell and cell-extracellular matrix interactions, such as those used in the treatment of cancer.

Another reason for ITGAD's potential as a drug target is its role in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis. ITGAD has been shown to be involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs.

ITGAD has also been shown to be involved in the regulation of the immune response. Its unique structure and function make it a potential target for drugs used in the treatment of autoimmune diseases.

Biomarker Potential

In addition to its potential as a drug target, ITGAD has also been identified as a potential biomarker. Its unique structure and function make it a potential marker for a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

One of the key advantages of ITGAD as a biomarker is its ability to be used in multiplex assays. This allows researchers to test for multiple markers in a single assay, which is useful for identifying potential biomarkers for complex diseases.

ITGAD has also been shown to be involved in the regulation of cellular processes, including cell adhesion and the regulation of the immune response. This makes ITGAD a potential biomarker for diseases that involve these processes, such as cancer and neurodegenerative diseases.

Conclusion

In conclusion, ITGAD is a protein that has unique structure and function, making it an attractive target for drug development. Its role in cell-cell and cell-extracellular matrix interactions, as well as its potential as a drug target and biomarker, make it an important molecule to study further. Further research into ITGAD's role in cellular processes and its potential as a drug and biomarker may lead to new treatments for a variety of diseases.

Protein Name: Integrin Subunit Alpha D

Functions: Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. May play a role in the atherosclerotic process such as clearing lipoproteins from plaques and in phagocytosis of blood-borne pathogens, particulate matter, and senescent erythrocytes from the blood

The "ITGAD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGAD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets